Sign In
Buy IPA
$1.62
+0 (+0%)
At Close: Jan 16, 2026
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
09:00am, Wednesday, 10'th Jan 2024
VICTORIA, BC / ACCESSWIRE / January 10, 2024 / ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), a leading company in AI-driven biotherapeutic research and technology, has recently provided an update to
ImmunoPrecise Antibodies Ltd. (IPA) Q2 2024 Earnings Call Transcript
12:40pm, Thursday, 14'th Dec 2023
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2024 Earnings Conference Call December 14, 2023 10:30 AM ET Company Participants Jennifer Bath - President and Chief Executive Officer Kristin Taylor - C
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
08:01am, Thursday, 14'th Dec 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
05:00pm, Friday, 08'th Dec 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced the closing of its $1.265
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
09:00am, Thursday, 07'th Dec 2023
VICTORIA, BC / ACCESSWIRE / December 7, 2023 / ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), a leading company in AI-driven biotherapeutic research and technology, has recently announced important ch
Why Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?
09:00am, Wednesday, 06'th Dec 2023
ImmunoPrecise Antibodies (NASDAQ: IPA ) stock is falling hard on Wednesday after the biotherapeutic company priced its shares in a public offering. This has ImmunoPrecise Antibodies offering 1.1 mil
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
07:00am, Wednesday, 06'th Dec 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) today announced that it has priced its und
New Strong Buy Stocks for October 23rd
08:16am, Monday, 23'rd Oct 2023
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
08:30am, Friday, 08'th Sep 2023
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today annou
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2023 Earnings Call Transcript
02:25pm, Friday, 07'th Jul 2023
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q4 2023 Earnings Conference Call July 7, 2023 10:30 AM ET Company Participants Jennifer Bath - CEO Barry Duplantis - VP-Client Relations Ilse Roodink - Chie
IPA to Present at Jefferies Healthcare Conference 2023
08:04am, Wednesday, 17'th May 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and t
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
11:28am, Thursday, 16'th Mar 2023
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023.
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
08:52am, Tuesday, 07'th Mar 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company
ImmunoPrecise Antibodies Ltd. (IPA) Q2 2023 Earnings Call Transcript
03:43pm, Thursday, 15'th Dec 2022
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2023 Earnings Conference Call December 15, 2022 10:30 AM ET Company Participants Jennifer Bath – Chief Executive Officer Barry Duplantis – Vice Presi
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
08:04am, Monday, 05'th Dec 2022
VICTORIA, British Columbia--( BUSINESS WIRE )--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today ann
